200 related articles for article (PubMed ID: 8823804)
1. Status of radiolabeled monoclonal antibodies for diagnosis and therapy of cancer.
Divgi CR
Oncology (Williston Park); 1996 Jun; 10(6):939-53; discussion 954, 957-8. PubMed ID: 8823804
[TBL] [Abstract][Full Text] [Related]
2. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
Behr TM; Sharkey RM; Juweid MI; Dunn RM; Ying Z; Zhang CH; Siegel JA; Gold DV; Goldenberg DM
Cancer Res; 1996 Apr; 56(8):1805-16. PubMed ID: 8620497
[TBL] [Abstract][Full Text] [Related]
3. Cancer imaging with radiolabeled antibodies: new advances with technetium-99m-labeled monoclonal antibody Fab' fragments, especially CEA-Scan and prospects for therapy.
Goldenberg DM; Juweid M; Dunn RM; Sharkey RM
J Nucl Med Technol; 1997 Mar; 25(1):18-23; quiz 34. PubMed ID: 9239599
[TBL] [Abstract][Full Text] [Related]
4. [Immunoscintigraphy and radioimmunotherapy of cancer using monoclonal antibodies].
Oriuchi N
Gan To Kagaku Ryoho; 1999 May; 26(6):762-7. PubMed ID: 10410144
[TBL] [Abstract][Full Text] [Related]
5. Radioimmunodetection and radioimmunotherapy of head and neck cancer.
Börjesson PK; Postema EJ; de Bree R; Roos JC; Leemans CR; Kairemo KJ; van Dongen GA
Oral Oncol; 2004 Sep; 40(8):761-72. PubMed ID: 15288829
[TBL] [Abstract][Full Text] [Related]
6. Immunoscintigraphy in patients with colorectal, ovarian, and prostate cancer. Results with site-specific immunoconjugates.
Maguire RT; Pascucci VL; Maroli AN; Gulfo JV
Cancer; 1993 Dec; 72(11 Suppl):3453-62. PubMed ID: 8242578
[TBL] [Abstract][Full Text] [Related]
7. [Radioimmunotargeting: diagnosis and therapeutic use].
Vuillez JP
Bull Cancer; 2000 Nov; 87(11):813-27. PubMed ID: 11125290
[TBL] [Abstract][Full Text] [Related]
8. Antibody-guided radiation therapy of cancer.
Koppe MJ; Postema EJ; Aarts F; Oyen WJ; Bleichrodt RP; Boerman OC
Cancer Metastasis Rev; 2005 Dec; 24(4):539-67. PubMed ID: 16408161
[TBL] [Abstract][Full Text] [Related]
9. Radioimmunodiagnosis and therapy.
Verhaar-Langereis MJ; Zonnenberg BA; de Klerk JM; Blijham GH
Cancer Treat Rev; 2000 Feb; 26(1):3-10. PubMed ID: 10660488
[TBL] [Abstract][Full Text] [Related]
10. Recent achievements in the development of radiolabeled monoclonal antibodies for diagnosis, therapy and biologic characterization of human tumors.
Larson SM; Macapinlac HA; Scott AM; Divgi CR
Acta Oncol; 1993; 32(7-8):709-15. PubMed ID: 8305216
[TBL] [Abstract][Full Text] [Related]
11. Pilot radioimmunotherapy trial with 131I-labeled murine monoclonal antibody CC49 and deoxyspergualin in metastatic colon carcinoma.
Divgi CR; Scott AM; Gulec S; Broussard EK; Levy N; Young C; Capitelli P; Daghighian F; Williams JM; Finn RD
Clin Cancer Res; 1995 Dec; 1(12):1503-10. PubMed ID: 9815950
[TBL] [Abstract][Full Text] [Related]
12. Radioimmunodetection and therapy of breast cancer.
DeNardo SJ
Semin Nucl Med; 2005 Apr; 35(2):143-51. PubMed ID: 15765377
[TBL] [Abstract][Full Text] [Related]
13. New insights into the pretargeting approach to image and treat tumours.
Patra M; Zarschler K; Pietzsch HJ; Stephan H; Gasser G
Chem Soc Rev; 2016 Nov; 45(23):6415-6431. PubMed ID: 27722526
[TBL] [Abstract][Full Text] [Related]
14. Indium-111 satumomab pendetide: the first FDA-approved monoclonal antibody for tumor imaging.
Bohdiewicz PJ
J Nucl Med Technol; 1998 Sep; 26(3):155-63; quiz 170-1. PubMed ID: 9755434
[TBL] [Abstract][Full Text] [Related]
15. Tumor pretargeting for radioimmunodetection and radioimmunotherapy.
Zhu H; Jain RK; Baxter LT
J Nucl Med; 1998 Jan; 39(1):65-76. PubMed ID: 9443740
[TBL] [Abstract][Full Text] [Related]
16. Principles of radioimmunotherapy for hematologists and oncologists.
Press OW; Rasey J
Semin Oncol; 2000 Dec; 27(6 Suppl 12):62-73. PubMed ID: 11226002
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of radiolabeled monoclonal antibodies in prostate cancer.
David KA; Milowsky MI; Kostakoglu L; Vallabhajosula S; Goldsmith SJ; Nanus DM; Bander NH
Clin Genitourin Cancer; 2006 Mar; 4(4):249-56. PubMed ID: 16729907
[TBL] [Abstract][Full Text] [Related]
18. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy.
Kosmas C; Snook D; Gooden CS; Courtenay-Luck NS; McCall MJ; Meares CF; Epenetos AA
Cancer Res; 1992 Feb; 52(4):904-11. PubMed ID: 1737353
[TBL] [Abstract][Full Text] [Related]
19. Exploration of novel strategies to enhance monoclonal antibodies targeting.
Khawli LA; Epstein AL
Q J Nucl Med; 1997 Mar; 41(1):25-35. PubMed ID: 9195850
[TBL] [Abstract][Full Text] [Related]
20. Immunoscintigraphy and radioimmunotherapy in Cuba: experiences with labeled monoclonal antibodies for cancer diagnosis and treatment (1993-2013).
Peña Y; Perera A; Batista JF
MEDICC Rev; 2014; 16(3-4):55-60. PubMed ID: 25208121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
